12:00 AM
Jan 23, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CDX-301: Phase I started

Celldex began an open-label, dose-escalation, U.S. Phase I trial to evaluate 1-75 mg/kg IV or subcutaneous CDX-301 for 5-10 days in about 30 healthy volunteers....

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >